Malignant Uterine Corpus Neoplasm — Trials

Malignant Uterine Corpus Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,571 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 411
Recruiting: 227
Ph III recruiting: 25
Growth YoY: +1%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 27.6%
Trials / 1,000 deaths: 50.2 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (168)

clinicaltrialsPublishedShowing 51–59 of 59 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00002920	S9630, Medroxyprogesterone in Treating Women With Breast Cancer	completed	Phase 3	313	SWOG Cancer Research NetworkNETWORK	1	Oct 31, 2012	clinicaltrials
NCT00002459	Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus	completed	Phase 3	224	European Organisation for Research and Treatment of Cancer - EORTCNETWORK	10	Sep 24, 2012